PTEN and prostate cancer: They detected homozygous deletions, frame shift, or nonsense mutations in PTEN in 63% (5/8) of glioblastoma cell lines, 100% (4/4) of prostate cancer cell lines, and 10% (2/20) of breast cancer cell lines.